• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    EDAP to Present at the Jefferies Global Healthcare Conference

    5/27/25 7:00:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $EDAP alert in real time by email

    AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City. 

    Presentation details:

    Date:Thursday, June 5th
    Time:4:20-4:50 PM ET
    Webcast:https://wsw.com/webcast/jeff319/edap/1824368

    The live and archived webcast of the presentation can be accessed in the Investors section of the Company's website here.

    About EDAP TMS SA

    A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com.

    Company Contact

    Blandine Confort

    Investor Relations / Legal Affairs

    EDAP TMS SA

    +33 4 72 15 31 50

    [email protected]

    Investor Contact

    John Fraunces

    LifeSci Advisors, LLC

    (917) 355-2395

    [email protected]



    Primary Logo

    Get the next $EDAP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EDAP

    DatePrice TargetRatingAnalyst
    5/15/2025Overweight → Neutral
    Piper Sandler
    4/4/2025$2.00Buy → Hold
    Jefferies
    11/1/2022$11.00Buy
    Jefferies
    11/19/2021$12.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDAP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • EDAP to Present at the Jefferies Global Healthcare Conference

      AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City.  Presentation details: Date:Thursday, June 5th Time:4:20-4:50 PM ET Webcast:https://wsw.com/webcast/jeff319/edap/1824368 The live and archived webcast of the presentation can be accessed in the Investors section of the Company's website here. About EDAP TMS SA A recognized leader in robotic energy-based therapies, EDAP TMS develops, ma

      5/27/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP Reports First Quarter 2025 Financial Results

                Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled Trial Presented at American Urology Association Annual Meeting (AUA 2025)Launched the New Focal One i Robotic HIFU System Performed World's First Remote Transcontinental Focal One Robotic HIFU Procedure Successfully AUSTIN, Texas, May 15, 2025 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the first quarter of 2025. "Demand for Focal One remai

      5/15/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025

      Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:                Thursd

      5/1/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care